InsidersTradesSigma
申报总数
公司
▲ 买入（5 笔）
▼ 卖出（2 笔）
内部人交易记录
其他已披露买入
5
已披露卖出
2
T+90 胜率
20%
T+90 平均收益
-22.8%
基于 5 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Explore the complete record of transactions filed by Smiley Joshua L, See Remarks. Director active across 1 company, notably Zai Lab Ltd. Cumulatively, 16 disclosures have been recorded. Split: 5 buys · 2 sells. Total volume traded: €822k. History available since 16 November 2023. The latest transaction was disclosed on 6 April 2026 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Smiley Joshua L
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报16 总计
3,017 股@ US$20.4480.0023% mcap8.9% 占其流量American Depositary SharesSEC:0000905148-26-001607:0
32,062 股American Depositary SharesSEC:0000905148-26-001546:0
7,145 股American Depositary SharesSEC:0000905148-26-001546:1
9,614 股@ US$20.3913.8% 占其流量American Depositary SharesSEC:0000905148-26-001546:2
6,388 股American Depositary SharesSEC:0000905148-26-001286:0
10,000 股@ US$28.910.011% mcap41.1% 占其流量American Depositary SharesSEC:0000905148-25-003326:0
标准退出：2025年12月9日 (T+90)
15,900 股American Depositary SharesSEC:0000905148-25-003061:0
7,145 股American Depositary SharesSEC:0000905148-25-001117:0
32,062 股American Depositary SharesSEC:0000905148-25-001077:0
15,900 股American Depositary SharesSEC:0000905148-24-002290:0
3,000 股@ US$21.405.6% 占其流量American Depositary SharesSEC:0000905148-24-001418:0
标准退出：2024年8月11日 (T+90)
7,145 股@ US$15.909.9% 占其流量American Depositary SharesSEC:0000905148-24-001114:0
3,000 股@ US$20.835.5% 占其流量American Depositary SharesSEC:0000905148-24-000853:0
标准退出：2024年5月30日 (T+90)
4,000 股@ US$29.9010.4% 占其流量American Depositary SharesSEC:0000905148-23-001614:0
标准退出：2024年3月13日 (T+90)
5,000 股@ US$26.9311.7% 占其流量American Depositary SharesSEC:0000905148-23-001471:0
标准退出：2024年2月14日 (T+90)
15,900 股American Depositary SharesSEC:0000905148-23-000761:0
16 条申报中的 16 条
About Smiley Joshua L
Smiley Joshua L. has an unspecified role at Zai Lab Ltd. His involvement in the company contributes to its strategic and operational objectives. Zai Lab is a biopharmaceutical company focused on developing innovative treatments for serious diseases.
